# Program 1 Architecture Review Track Phase G - Privacy, PHI/PII, and Real-Data Governance Conceptual Boundary

Status: documentation-only, synthetic-only, non-production, non-runtime, pre-implementation, conceptual privacy/PHI/PII/real-data governance boundary. Not a privacy clearance, not PHI/PII processing approval, and not real-data governance approval.

## Purpose

Program 1 Architecture Review Track Phase G defines conceptual privacy, PHI/PII, and real-data governance boundaries for any possible future Program 1 implementation discussion.

Phase G follows Architecture Review Track Phase A, Phase B, Phase C, Phase D, Phase E, and Phase F. It is not Phase Z+1 and is not a return to the Phase V-Z governance/prototype sequence.

Program 1 remains in pre-implementation hold.

## Track continuity

Phase A established the synthetic-only architecture boundary. Phase B established conceptual module separation. Phase C established conceptual synthetic data-flow traces. Phase D established a conceptual read-only reference boundary and strict non-mutation model. Phase E established human-in-the-loop responsibility and clinical accountability boundaries. Phase F established conceptual security, authorization, and audit boundaries. Phase G clarifies that privacy, PHI/PII handling, real-data governance, de-identification, anonymization, pseudonymization, data retention, consent, and data-subject rights are future conceptual areas only.

## Scope

- Privacy conceptual boundary.
- PHI/PII processing prohibition.
- Real-data governance conceptual boundary.
- De-identification, anonymization, and pseudonymization prohibition.
- Consent, retention, and data-subject rights conceptual limits.
- Privacy and real-data dependency map.
- Privacy control matrix.

## Non-scope

Phase G does not add runtime code, tests, helpers, scripts, imports, services, database migrations, API endpoints, UI flows, schedulers, task runners, integrations, data connectors, real-data ingestion, real patient data processing, PHI/PII processing, de-identification tooling, anonymization pipeline, pseudonymization pipeline, consent management tooling, privacy enforcement runtime, retention enforcement runtime, data-subject rights workflow, read-only runtime access, database queries, EHR/EMR access, clinical decision execution, autonomous diagnosis, autonomous treatment, patient instruction delivery, clinician-facing executable recommendations, runtime authentication, runtime authorization, runtime access control, runtime policy enforcement, runtime auth/authz/RBAC, audit logging runtime behavior, audit event capture, audit event storage, access log capture, patient messaging, appointment mutation, workflow enforcement, Task engine, Outcome Evidence, clinical write workflows, approval/clearance/override runtime capability, approval gate implementation, clearance gate implementation, override gate implementation, production-readiness claim, or go-live authorization.

## Safety boundaries

Phase G is documentation-only, synthetic-only, non-production, non-runtime, pre-implementation, and conceptual only.

Phase G does not approve production use, real patient data, PHI/PII processing, real-data governance clearance, privacy/legal clearance, live clinical deployment, runtime implementation, runtime data flow, read-only runtime access, data connectors, de-identification tooling, anonymization tooling, pseudonymization tooling, consent tooling, retention tooling, or go-live.

## Phase A/B/C/D/E/F input summary

Phase A established synthetic-only architecture boundaries, permitted future discussion areas, prohibited runtime paths, data classification preview, read-only vs write-capable conceptual distinction, human-in-the-loop responsibility preview, and a future approval dependency map.

Phase B established conceptual module separation, the synthetic documentation layer boundary, future read-only layer boundary, future clinical review layer boundary, prohibited write-capable layer boundary, prohibited patient communication boundary, prohibited appointment mutation boundary, deferred security/audit/authorization layer, and prohibited coupling map.

Phase C established the synthetic entity model, conceptual data-flow model, allowed synthetic trace paths, prohibited real-data flow paths, read-only conceptual flow boundary, write-back and mutation prohibition trace, security/audit/auth conceptual flow limits, and boundary trace matrix.

Phase D established the conceptual read-only reference boundary, non-mutation model, prohibited read access paths, prohibited write-back and mutation paths, read-only vs operational access distinction, and synthetic reference trace matrix.

Phase E established the human-in-the-loop responsibility model, clinical accountability boundary, autonomous clinical behavior prohibition, clinician review and decision separation, patient instruction and communication prohibition, accountability dependency map, and clinical boundary matrix.

Phase F established security conceptual boundary, authorization and RBAC conceptual boundary, audit conceptual boundary, policy enforcement prohibition, approval/clearance/override prohibition, security/auth/audit dependency map, and conceptual control matrix.

## Privacy conceptual boundary

Privacy is a future conceptual architecture domain only. It may be discussed as privacy principles, data minimization concepts, purpose limitation concepts, future privacy/legal review dependencies, data-subject rights concepts, retention concepts, and non-runtime governance notes.

Phase G must not create privacy tooling, privacy enforcement runtime, consent management tooling, data-subject rights workflow, retention enforcement runtime, real-data processing, PHI/PII processing, or compliance claims.

## PHI/PII processing prohibition

PHI/PII processing is prohibited in Phase G. Phase G prohibits real patient data ingestion, real patient data processing, PHI/PII processing, production dataset use, imported clinic data, EHR/EMR extracts, appointment data extracts, patient messages, clinical notes, real audit logs, real authorization logs, patient-derived examples, and real-world case vignettes derived from identifiable or clinic data.

## Real-data governance conceptual boundary

Real-data governance is a future conceptual dependency only. Phase G does not approve real patient data, real-data governance clearance, real-data integration, real-data inspection, EHR/EMR access, production database access, or operational access.

## De-identification, anonymization, and pseudonymization prohibition

De-identification, anonymization, and pseudonymization are future conceptual topics only. Phase G does not implement de-identification tooling, anonymization tooling, pseudonymization tooling, pipelines, transformations, validators, datasets, or claims that data is de-identified, anonymized, pseudonymized, or ready for use.

## Consent, retention, and data-subject rights conceptual limits

Consent, retention, and data-subject rights are future conceptual topics only. Phase G does not implement consent workflows, retention workflows, deletion workflows, access request workflows, rectification workflows, portability workflows, restriction workflows, objection workflows, or privacy enforcement.

## Privacy and real-data dependency map

| Area | Current Phase G status | Unresolved dependency | Prohibited current action | Required future review | Current decision |
| --- | --- | --- | --- | --- | --- |
| Privacy/legal review | Not performed | Privacy/legal governance | Claim privacy clearance | Privacy/legal review | Deferred |
| PHI/PII governance | Conceptual only | PHI/PII approval path | Process PHI/PII | Privacy/legal review | Prohibited |
| Real-data governance | Conceptual only | Real-data approval path | Ingest or process real data | Data governance review | Prohibited |
| De-identification review | Conceptual only | De-identification methodology review | Implement de-identification tooling | Privacy/legal review | Deferred |
| Anonymization review | Conceptual only | Anonymization methodology review | Implement anonymization pipeline | Privacy/legal review | Deferred |
| Pseudonymization review | Conceptual only | Pseudonymization methodology review | Implement pseudonymization pipeline | Privacy/legal review | Deferred |
| Consent model | Conceptual only | Consent/legal basis model | Implement consent tooling | Privacy/legal review | Deferred |
| Retention model | Conceptual only | Retention schedule and policy | Implement retention enforcement | Privacy/legal and operations review | Deferred |
| Data-subject rights model | Conceptual only | Rights workflow model | Implement rights workflow | Privacy/legal and operations review | Deferred |
| Data minimization | Conceptual only | Minimization policy | Collect real data | Privacy/legal review | Deferred |
| Purpose limitation | Conceptual only | Purpose limitation policy | Reuse data for undefined purpose | Privacy/legal review | Deferred |
| Access governance | Conceptual only | Access governance model | Grant data access | Security/privacy review | Deferred |
| Audit dependency | Conceptual only | Audit model | Capture real audit/access logs | Audit/security/privacy review | Deferred |
| Incident response dependency | Conceptual only | Privacy incident model | Trigger incident workflow | Privacy/legal and operations review | Deferred |
| Deployment governance | Not performed | Deployment governance model | Authorize deployment | Production governance review | Deferred |

## Privacy control matrix

| Privacy concept | Allowed in Phase G | Prohibited in Phase G | Data status | Runtime status | Enforcement status | Future dependency | Current decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Privacy principle | Conceptual discussion | Privacy tooling | Synthetic only | None | None | Privacy/legal review | Allowed as docs only |
| PHI/PII boundary | Prohibition discussion | PHI/PII processing | No PHI/PII | None | None | Privacy/legal review | Prohibited |
| Real-data boundary | Prohibition discussion | Real-data ingestion | Synthetic only | None | None | Data governance review | Prohibited |
| De-identification concept | Conceptual discussion | De-identification tooling | Synthetic only | Not implemented | None | Privacy/legal review | Deferred |
| Anonymization concept | Conceptual discussion | Anonymization pipeline | Synthetic only | Not implemented | None | Privacy/legal review | Deferred |
| Pseudonymization concept | Conceptual discussion | Pseudonymization pipeline | Synthetic only | Not implemented | None | Privacy/legal review | Deferred |
| Consent concept | Conceptual discussion | Consent workflow | Synthetic only | Not implemented | None | Privacy/legal review | Deferred |
| Retention concept | Conceptual discussion | Retention enforcement | Synthetic only | Not implemented | None | Privacy/legal and operations review | Deferred |
| Data-subject rights concept | Conceptual discussion | Rights workflow | Synthetic only | Not implemented | None | Privacy/legal and operations review | Deferred |
| Data minimization concept | Conceptual discussion | Data collection | Synthetic only | Not implemented | None | Privacy/legal review | Deferred |
| Purpose limitation concept | Conceptual discussion | Purpose expansion | Synthetic only | Not implemented | None | Privacy/legal review | Deferred |
| Access governance concept | Conceptual discussion | Runtime access grant | Synthetic only | Not implemented | None | Security/privacy review | Deferred |
| Privacy incident concept | Conceptual discussion | Incident automation | Synthetic only | Not implemented | None | Privacy/legal and operations review | Deferred |
| Deployment concept | Boundary discussion | Production deployment | None | Prohibited | Prohibited | Production governance review | Prohibited |

## Explicit non-approval statement

Phase G does not approve implementation, production use, real-data use, PHI/PII processing, clinical deployment, go-live, runtime data flow, database access, EHR/EMR access, privacy tooling, de-identification tooling, anonymization pipeline, pseudonymization pipeline, consent workflow, retention workflow, runtime authorization, runtime audit logging, or approval/clearance/override capability.

## Next-step decision

Recommended next phase: `Program 1 Architecture Review Track Phase H - Deployment, Environment, and Release Governance Conceptual Boundary`.

If opened, Phase H should remain documentation-only and synthetic-only. Phase H must not introduce deployment automation, environments, CI/CD gates, production configuration, secrets, infrastructure, release workflow, or go-live readiness.

## Closure statement

Architecture Review Track Phase G closes with Program 1 still in pre-implementation hold. No runtime behavior, real-data ingestion, PHI/PII processing, privacy tooling, de-identification tooling, anonymization pipeline, pseudonymization pipeline, consent workflow, retention workflow, production approval, clinical deployment, approval/clearance/override capability, or go-live authorization is created.
